Filana Therapeutics, Inc.,

Filana Therapeutics is a clinical‑stage biotechnology company focused on the research and development of investigational therapies for central nervous system disorders. Their lead program, simufilam, is an orally administered, proprietary small‑molecule investigational drug being studied in indications including tuberous sclerosis complex (TSC)‑related epilepsy, with potential applicability…More in other CNS conditions. Simufilam is designed to modulate the activity of filamin A (FLNA), a protein involved in key neuronal processes.